Orexo AB (publ)
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:1845 tCO2e/year (2023)
Scope 1 Emissions:273 tCO2e/year (2023)
Scope 2 Emissions:73 tCO2e/year (2023)
Scope 3 Emissions:1500 tCO2e/year (2023)
Renewable Energy Share:94.9% (2023)
Total Energy Consumption:3104.2 MWh/year (2023)
Waste Generated:6083 kg/year (2023)
ESG Focus Areas
- Access to healthcare
- Ethical business
- Responsible manufacturing
- Climate change
- Responsible procurement
- Wellbeing for employees
Environmental Achievements
- Reduced greenhouse gas emissions by 3.2% (scope 1 and 2) and 10% (scope 1-3) from 2022.
- 100% of commercial suppliers have approved sustainability assessments.
- Completed mapping of scope 3 emissions according to the Greenhouse Gas Protocol.
Social Achievements
- Improved access to Zubsolv in the public payer segment (from 48% to 50%).
- 8 out of 10 employees are satisfied with working at Orexo.
- MODIA and Vorvida added to the VA’s Federal Supply Schedule (as of January 2024).
Governance Achievements
- All employees signed and confirmed understanding and adherence to the Business Compliance and Ethics Code.
- Won patent litigation against Sun Pharmaceuticals for Zubsolv in the US (appealed by Sun).
Climate Goals & Targets
Long-term Goals:
- Reduce greenhouse gas emissions by 50% (scope 1 and 2) and 20% (scope 1-3) by 2030.
Medium-term Goals:
- At least one drug based on AmorphOX platform reaching global markets by 2030.
- 100% reimbursement for Orexo’s pharmaceutical products and growing share in Medicaid segment by 2030.
Short-term Goals:
- EBITDA profitability for FY 2024.
- Launch of OX124 in late 2024 (pending FDA approval).
Environmental Challenges
- Supply chain disruptions due to geopolitical risks.
- Digital mental health programs not meeting expectations.
- Lower overall market development impacting Zubsolv sales.
- MODIA study did not meet primary endpoints.
Mitigation Strategies
- Contingency plans to minimize supply chain disruptions.
- Restructuring of digital mental health programs, full integration into US Commercial business in 2024.
- Improved market access for Zubsolv in Medicaid.
- Analysis of MODIA study data and program update to comply with FDA regulations.
Supply Chain Management
Supplier Audits: 100% of commercial suppliers have an approved sustainability assessment.
Responsible Procurement
- Supplier Code of Conduct
- Sustainability assessment processes
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: UN Global Compact
Certifications: Socially sustainable company (Sustainalytics, March 2024)
Third-party Assurance: Ernst & Young Aktiebolag
UN Sustainable Development Goals
- SDG 3: Good health and well-being
Focus on OUD and mental health treatment, access to care, and development of innovative medications.
Sustainable Products & Innovation
- OX124 (high-dose naloxone rescue medication)
- OX640 (epinephrine product for allergic reactions)